Neuren Pharmaceuticals (ASX:NEU) Wins CHMP Backing, Is The Upside Already Priced In?

Neuren Pharmaceuticals (ASX:NEU) is back in focus after the European Medicines Agency’s CHMP issued a positive opinion on its Rett syndrome treatment Daybue, clearing the path toward potential approval and European launch.

See our latest analysis for Neuren Pharmaceuticals.

That CHMP opinion has coincided with a sharp shift in sentiment toward Neuren Pharmaceuticals. The 7 day share price return of 36.82% and 90 day share price return of 46.72% contrast with a year to date share price decline of 6.66% and a very large 5 year total shareholder return, suggesting renewed momentum after a softer patch.

If this kind of regulatory catalyst has your attention, it could be a good moment to widen your watchlist with our screener of 9 healthcare AI stocks.

So with Neuren Pharmaceuticals now sitting at A$17.65, trading at a discount to an A$24.33 analyst price target and with a strong 5 year total shareholder return, is there still an opportunity here or is the market already pricing in future growth?

Most Popular Narrative: 24.7% Undervalued

On the latest estimates, Neuren Pharmaceuticals has a narrative fair value of A$23.45 against a last close of A$17.65, which frames the current rally in a different light.

The analysts have a consensus price target of A$24.512 for Neuren Pharmaceuticals based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of A$30.5, and the most bearish reporting a price target of just A$21.2.

Read the complete narrative.

Want to understand why this narrative still points to upside at a higher discount rate, softer revenue assumptions and richer future earnings multiples than before? The story blends rapid profit growth expectations, very high forecast margins and a premium P/E that sits above the sector. The interesting part is how all of that still nets out to an A$23.45 fair value.

Result: Fair Value of A$23.45 (UNDERVALUED)

Have a read of the narrative in full and understand what’s behind the forecasts.

However, Neuren Pharmaceuticals still faces meaningful risks, including its heavy reliance on Acadia for DAYBUE royalty income, as well as potential regulatory setbacks for NNZ-2591 and other indications.

Find out about the key risks to this Neuren Pharmaceuticals narrative.

Another View on Neuren Pharmaceuticals: Rich Multiples, Different Story

While the Neuren Pharmaceuticals narrative fair value points to the shares being 24.7% undervalued, the current P/E of 73.3x tells a more cautious story. That multiple is well above the 20.6x global pharmaceuticals average and the 30.3x peer average, as well as an estimated fair ratio of 45x. This suggests a lot of future success is already reflected in the price. The question is whether you see that gap as valuation risk or a premium you are prepared to pay.

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

The mix of optimism and caution around Neuren Pharmaceuticals is clear, so review the numbers yourself and shape your own view using our breakdown of 3 key rewards

Looking for more investment ideas beyond Neuren Pharmaceuticals?

If Neuren Pharmaceuticals has sharpened your focus on quality opportunities, do not stop here. Broaden your watchlist with structured ideas that match your goals.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com